Glucose induced ApoB100/ApoAI ratio changes in cultured HepG2 cells in vitro

<ns3:p> <ns3:bold>Backgroundː</ns3:bold> Numerous <ns3:italic>in vivo</ns3:italic> human cohort studies have suggested that the apolipoprotein B100/apolipoprotein AI (ApoB100/ApoAI) ratio might be a risk factor in coronary heart disease. The aim of this study was to measure ApoB100/ApoAI ratio changes in cell secretions by incubating HepG2 cells with various amounts of glucose <ns3:italic>in vitro</ns3:italic> . </ns3:p> <ns3:p> <ns3:bold>Methods</ns3:bold> <ns3:bold>ː</ns3:bold> HepG2 cells were cultured in low-, normal- or high-glucose Dulbecco's Modified Eagle Medium (DMEM) (1, 4.5 and 10g/L, respectively). Levels of ApoAI and ApoB100 were measured with commercial sandwich enzyme-linked immunosorbent assay kits (cat#: H0123 and H0124) from ShangHai MEIXUAN Biological Science and Technology Ltd (Shanghai, China). Experiments were repeated six times for each assay. </ns3:p> <ns3:p> <ns3:bold>Resultsː</ns3:bold> The results showed that ApoB100/ApoAI ratio have positive correlations with the glucose concentration increase. </ns3:p> <ns3:p> <ns3:bold>Conclusionsː</ns3:bold> A higher concentration of glucose induced an undesirable ApoB100/ApoAI ratio change, which suggests a new regulatory pathway in lipoprotein catabolism and provides a cell model for further mechanism study. This finding may lead to novel therapeutic ways for diagnosis and treatment for coronary artery disease. </ns3:p>